No Data
Express News | Zhixiang Jintai: Intends to repurchase -40 million yuan of shares.
Zhixiang Jintai (688443.SH): Not yet implemented share repurchase.
Gelonghui November 4th | Zhixiang Jintai (688443.SH) announced that as of October 31, 2024, the company has not yet implemented share repurchases.
Zhixiang Jintai-U (688443): Saileqi sales exceed expectations, commercialization achievements beginning to show.
Introduction of this report: After the rapid increase in sales volume of the salekichimab in late August, initial commercialization achievements are starting to show. The pipeline under research is steadily progressing, and the NDA for the dual-specificity antibody against rabies virus is imminent, expected to contribute to performance growth. Maintain a "shareholding" rating. Investment.
Zhixiang Jintai: Third Quarter Report 2024
Third Quarter Report 2024
Zhixiang Jintai (688443.SH): a net loss of 0.546 billion yuan in the first three quarters.
GeLongHui October 30th | ZhiXiangJinTai (688443.SH) announced that the company achieved revenue of 12.49 million yuan in the first three quarters, an increase of 8875.4% year-on-year; net income attributable to parent company -0.546 billion yuan; non-recurring net income attributable to parent company -0.55 billion yuan.
No Data
No Data